|
51 |
Oral Supplementation with <sc>l</sc>-Cystine, Serenoa repens, Cucurbita pepo, and Pygeum africanum in Chronic Telogen Effluvium and Androgenetic Alopecia: A Double-Blind, Placebo-Controlled, Randomized Clinical Study
Enthalten in Skin appendage disorders Bd. 11, 2025, Nr. 1: 27-35. 9 S.
|
|
|
|
52 |
Unspezifische Effekte in der Physiotherapie
Enthalten in VPT-Magazin Bd. 11, 2025, Nr. 01: 20-23
|
|
|
|
53 |
Plaque-Psoriasis: Langzeitdaten bestätigen positives Sicherheitsprofil von Deucravacitinib
Enthalten in Kompass Autoimmun Bd. 7, 2025, Nr. 2: 68-71. 4 S.
|
|
|
|
54 |
Deucravacitinib zeigt eine höhere Wirksamkeit und Sicherheit bei kutanem Lupus erythematodes im Vergleich zu verschiedenen Biologika und niedermolekularen Wirkstoffen: systematische Übersicht und Metaanalyse
Enthalten in Kompass Autoimmun Bd. 7, 2025, Nr. 2: 59-67. 9 S.
|
|
|
|
55 |
From guidelines to evidence-based practice – A German perspective on mesalazine as first-line therapy for mild-to-moderate ulcerative colitis
Enthalten in Zeitschrift für Gastroenterologie 16.06.2025
|
|
|
|
56 |
Dose-extending placebo effect in a rat model of buprenorphine maintenance treatment
Enthalten in Psychopharmacology 21.5.2025: 1-12
|
|
|
|
57 |
Altersbedingte Makuladegeneration – Teil 2: therapeutische Optionen bei der AMD
Enthalten in Klinische Monatsblätter für Augenheilkunde 19.05.2025
|
|
|
|
58 |
The efficacy of elevating anandamide via inhibition of fatty acid amide hydrolase (FAAH) combined with internet-delivered cognitive behavioral therapy in the treatment of post-traumatic stress disorder: a randomized, placebo-controlled clinical trial
Enthalten in Neuropsychopharmacology 17.5.2025: 1-9
|
|
|
|
59 |
A randomized, double-blind, placebo-controlled phase III study evaluating the preventive effect of diclofenac cream on capecitabine-related hand-foot syndrome: study protocol of J-SUPPORT2401/JORTC-SUP06 (J-DIRECT)
Enthalten in International journal of clinical oncology 14.5.2025: 1-9
|
|
|
|
60 |
The Efficacy and Safety of BCD-180, an Anti-TRBV9+ T cell Monoclonal Antibody, in Patients with Active Radiographic Axial Spondyloarthritis: 36-week Results from the Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Study ELEFTA
Enthalten in Doklady biochemistry and biophysics 11.5.2025: 1-17
|
|
Administration
